[Preoperative administration of new GPIIb/IIIa inhibitors]

Kongressbd Dtsch Ges Chir Kongr. 2001:118:584-8.
[Article in German]

Abstract

The influence of preoperative abciximab treatment on perioperative risks was analyzed. Six groups were formed in consecutive patients (n = 957, 1/1994-3/2000) operated upon for CABG according to the urgency of the intervention and the type of preoperative haemostaseological treatment. Thirty-one patients underwent urgent/emergency CABG with preceding abciximab treatment. After pretreatment with abciximab the surgical results did not differ from patients with other types of preoperative haemostaseological treatment. CABG can be performed with similar results in abciximab pretreated patients as in patients with other types of preoperative haemostaseological treatment.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study

MeSH terms

  • Abciximab
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Blood Loss, Surgical / physiopathology*
  • Coronary Artery Bypass*
  • Humans
  • Immunoglobulin Fab Fragments / administration & dosage*
  • Immunoglobulin Fab Fragments / adverse effects
  • International Normalized Ratio
  • Partial Thromboplastin Time
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Premedication

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Abciximab